1-7 of 7
Ling Cai
Close
Sort by
Journal Articles

Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Priyanka Gaitonde, Ling Cai, Paulo de Miranda, Jack Roos, Simon Rule, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3646–3647.
https://doi.org/10.1182/blood-2022-169661
Published: 2022
Journal Articles

Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Matthew S. Davids, Ugochinyere Emeribe, Priyanka Gaitonde, Ling Cai
Journal: Blood
Blood (2021) 138 (Supplement 1): 2633.
https://doi.org/10.1182/blood-2021-146976
Published: 2021
Journal Articles

A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients

John F. Seymour, Priyanka Gaitonde, Ugochinyere Emeribe, Ling Cai, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3722.
https://doi.org/10.1182/blood-2021-147112
Published: 2021
Journal Articles

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation

Zhihong Ren, Jeong Hyun Ahn, Hequn Liu, Yi-Hsuan Tsai, Natarajan V. Bhanu, Brian Koss, David F. Allison, Anqi Ma, Aaron J. Storey, Ping Wang, Samuel G. Mackintosh, Ricky D. Edmondson, Richard W. J. Groen, Anton C. Martens, Benjamin A. Garcia, Alan J. Tackett, Jian Jin, Ling Cai, Deyou Zheng, Gang Greg Wang
Journal: Blood
Blood (2019) 134 (14): 1176–1189.
https://doi.org/10.1182/blood.2019000578
Published: 2019
Includes: Supplemental data
Journal Articles

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL- rearranged leukemia

Bowen Xu, Doan M. On, Anqi Ma, Trevor Parton, Kyle D. Konze, Samantha G. Pattenden, David F. Allison, Ling Cai, Shira Rockowitz, Shichong Liu, Ying Liu, Fengling Li, Masoud Vedadi, Stephen V. Frye, Benjamin A. Garcia, Deyou Zheng, Jian Jin, Gang Greg Wang
Journal: Blood
Blood (2015) 125 (2): 346–357.
https://doi.org/10.1182/blood-2014-06-581082
Published: 2015
Includes: Supplemental data
Journal Articles

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

Aaron P. Rapoport, MD, Nicole A. Aqui, MD, Edward A. Stadtmauer, MD, Ashraf Z. Badros, MD, Dan T. Vogl, MD, MSCE, YinYan Xu, Brendan M Weiss, MD, Ling Cai, PhD, Hong-Bin Fang, PhD, Elizabeth Veloso, RN, JD, Zhaohui Zheng, MA, Saul Yanovich, MD, Gorgun Akpek, MD, MHS, Sunita Philip, Kathleen Ruehle, RN, Kelly-Marie Betts, MS, Anne Chew, PhD, Holly McConville, RN, BSN, Sandra Westphal, Scott Strome, Andres Salazar, MD, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2012) 120 (21): 352.
https://doi.org/10.1182/blood.V120.21.352.352
Published: 2012
Journal Articles

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Clinical Trials & Observations
Aaron P. Rapoport, Nicole A. Aqui, Edward A. Stadtmauer, Dan T. Vogl, Hong-Bin Fang, Ling Cai, Stephen Janofsky, Anne Chew, Jan Storek, Gorgun Akpek, Ashraf Badros, Saul Yanovich, Ming T. Tan, Elizabeth Veloso, Marcela F. Pasetti, Alan Cross, Sunita Philip, Heather Murphy, Rita Bhagat, Zhaohui Zheng, Todd Milliron, Julio Cotte, Andrea Cannon, Bruce L. Levine, Robert H. Vonderheide, Carl H. June
Journal: Blood
Blood (2011) 117 (3): 788–797.
https://doi.org/10.1182/blood-2010-08-299396
Published: 2011
Includes: Supplemental data